Sat, Dec 20, 2014, 7:26 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

CytRx Corporation Message Board

  • markt929 markt929 May 11, 2013 12:26 AM Flag

    The fundamental value of CYTR have been changed/disclosed by the tamibarotene Phase 2b trial for NSCLC

    Let’s have a look at the following news/announcements.
    1. On June 26, 2012 at 12:58 AM, "We've achieved a key milestone in advancing the late-stage clinical development of tamibarotene in a significant oncology indication that claims more lives than breast, prostate and ovarian cancer combined," said CytRx CEO Steven A. Kriegsman. "We expect to report data from the global Phase 2b clinical trial in 2013. There is no question that effective treatment of metastatic NSCLC is a major unmet medical need and that tamibarotene in this indication could represent an important market opportunity for CytRx and our shareholders." "We are optimistic about tamibarotene's prospects in advanced NSCLC based on clinical data indicating a statistically significant improvement in these patients when all-trans retinoic acid (ATRA) was combined with paclitaxel and cisplatin," said Daniel Levitt, MD, Ph.D., CytRx's Chief Medical Officer. "Tamibarotene appears to be 10-times more potent than ATRA and was designed to avoid several of the toxic side effects of ATRA by selectively binding to specific molecular receptors.
    2. The paper published in the Journal of Clinical Oncology by a Mexican research group, Arrieta (the principal investigator for CytRx's clinical trial) et al (June 17, 2010), claimed that “ATRA added to a regimen of paclitaxel plus cisplatin to a regimen of paclitaxel plus cisplatin alone as a treatment for patients with advanced NSCLC. The group administered ATRA plus the chemotherapeutic agents showed improved response rates of 55.8% versus 25.4%, and increased progression-free survival of 8.9 months versus 6.0 months. Median overall survival was increased from 9.5 months to 23.5 months when ATRA was added to the above chemotherapy regimen, representing a 14-month median extension of life.
    3. However, on May 08, 2013, based on an interim analysis indicating that patients treated with tamibarotene were unlikely to show improved progression-free survival over treatment with approved chemotherapeutic agents.
    "We are disappointed by the outcome of the tamibarotene trial for our Company, but more importantly for patients. The trial was well-conducted but the DSMC judged that it would not be able to successfully meet its primary endpoint…” said CytRx CEO Steven A. Kriegsman.
    Our questions are: Why and how did “the DSMC judged that it would not be able to successfully meet its primary endpoint”? How could the results so different between the tamibarotene Phase 2b trial for NSCLC and the paper of Arrieta et al (June 17, 2010, the Journal of Clinical Oncology)?
    The fundamental value of CYTR have been changed/disclosed by the tamibarotene Phase 2b trial for NSCLC! The leftover of the value of CYTR stock is nothing but gambling!

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
CYTR
2.55-0.01(-0.39%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.